fashion -WSS

fashion

author：leisure time 2025-10-03 00:03:49 - browse：1

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Parkinson’s finding may lead to tests and, someday, treatments

focus

WSS

Be careful with at

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

How digital therapeutics firms are pivoting after Pear's bankruptcy

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Be careful with at

Montana youths win climate lawsuit against state for promoting fossil fuels

Wikipedia

fashion

entertainment

Heart attack and stroke risk calculators need revising

AI generated plenty of interest at JPM but not a lot of trust

Bright Health sells Medicare Advantage business to Molina

AI generated plenty of interest at JPM but not a lot of trust

BioMarin wins approval for gene therapy to treat hemophilia A

Prior authorization will have to move faster under new Biden rule

Anesthesiologist group: stop taking Ozempic before surgery

Dewpoint Therapeutics lays off staff after losing partnerships

Psychedelics group wrestles with new pharma identity

Biden administration begins canceling student loan debt for 804,000 borrowers

hotspot

Dewpoint Therapeutics lays off staff after losing partnerships

Novo Nordisk touts Wegovy study, but still struggling with supply

Independent physicians launch a new lobbying group

After Optum profits sink, UnitedHealth makes changes

After Optum profits sink, UnitedHealth makes changes

How digital therapeutics firms are pivoting after Pear's bankruptcy

explore

explore

focus

Wikipedia